Structural Mechanisms and Allosteric Modulation of Metabotropic Glutamate Receptor 5

Structural Biology Background and Academic Trajectory

• Educational and Research Background of the Investigator:

  • Undergraduate education completed at Stella Maris College in Chennai, earning a bachelor's degree in biochemistry and chemistry.

  • Master's degree completed in human biology at Sri Ramachandra University.

  • Doctoral training (PhD) completed at the University of Sydney under the supervision of Dave Gurl, focusing on iron-chelating hemoglobins expressed in bacteria that function to scavenge iron.

  • Postdoctoral research conducted in Melbourne at the Walter and Eliza Hall Institute (WEHI) with Jackie Gulbis, utilizing X-ray crystallography to investigate receptor biochemistry and membrane protein structural biology.

  • Awarded a CJ Martin Early Career Fellowship from Australia, a program that historically funded two years of overseas postdoctoral research followed by repatriation (a fellowship scheme that is no longer offered).

  • Postdoctoral fellowship at Stanford University in the laboratory of Brian Kobilka (recipient of the 2012 Nobel Prize in Chemistry for G protein-coupled receptor [GPCR] structure and function).

  • Key accomplishments in the Kobilka laboratory include resolving the first active-state signaling structure of the cannabinoid receptor ($CB_1$), elucidating structural mechanisms of receptor-mediated G protein activation, investigating accessory protein regulation of class B receptors (such as the glucagon receptor), and dissecting step-by-step activation mechanisms of metabotropic glutamate receptors.

  • Current appointment: Established an independent laboratory at Weill Cornell Medicine focusing on structure-guided design for safer therapeutics, utilizing high-resolution cryo-electron microscopy (cryo-EM) to interrogate receptor signaling networks.

G Protein-Coupled Receptor (GPCR) Families and Architectures

• Physiological Significance and Pharmacological Impact of GPCRs:

  • GPCRs represent the largest family of integral membrane proteins in the human genome, serving as primary communication interfaces that translate extracellular cues into intracellular biochemical cascades.

  • GPCR signaling regulates critical physiological processes, including:

    • Neurotransmitter release across central and peripheral synapses.

    • Immune cell activation and inflammatory responses.

    • Vascular tone, cardiac muscle contraction, and blood pressure homeostasis.

    • Endocrine hormone secretion.

  • Receptors within this superfamily are targeted by approximately $34\%$ of all United States Food and Drug Administration (FDA)-approved therapeutics.

• Structural Classification of GPCR Superfamily:

  • All GPCRs share a conserved structural core consisting of seven transmembrane ($7\text{TM}$) $\alpha$-helices traversing the lipid bilayer.

  • Based on sequence homology and functional divergence, GPCRs are categorized into five distinct families:

    • Family A: Rhodopsin-like.

    • Family B: Secretin-like.

    • Family C: Metabotropic glutamate-like.

    • Adhesion.

    • Frizzled/Taste2.

• Comparative Architectural Profiles Across Select Families:

  • Family A (Rhodopsin):

    • Prototypical receptors include the $\beta_2$-adrenergic receptor and the cannabinoid $CB_1$ receptor.

    • Possess a compact extracellular architecture.

    • Ligands are predominantly small molecules that penetrate directly into the orthosteric pocket situated deep within the $7\text{TM}$ bundle.

  • Family B (Secretin):

    • Prototypical receptors include the glucagon receptor ($\text{GCGR}$) and the glucagon-like peptide-1 receptor ($\text{GLP-1R}$), targeted by therapeutic peptide agonists such as semaglutide.

    • Feature an extended extracellular domain (ECD) dedicated to capturing peptide ligands, presenting them into the $7\text{TM}$ core for receptor engagement.

  • Family C (Metabotropic Glutamate):

    • Exist strictly as obligate dimers (homodimers or heterodimers).

    • Possess very large, modular extracellular domains positioned far above the lipid bilayer.

    • The orthosteric agonist binds exclusively at the distal apex of the extracellular domain.

    • Agonist binding triggers structural rearrangements that must propagate through intervening structural domains to the $7\text{TM}$ bundles across a distance of approximately $120\,\text{\AA}$ to recruit and activate intracellular G proteins.

Architecture and Activation Mechanism of Metabotropic Glutamate Receptor 5 ($mGlu_5$)

• Physiological and Pathological Roles of $mGlu_5$:

  • $mGlu_5$ is a prototypical Family C GPCR critically involved in synaptic plasticity, particularly the acquisition and retention of long-term memory.

  • Constitutes an important therapeutic target for neurodegenerative and psychiatric disorders, including Alzheimer's disease, major depressive and mood disorders, anxiety disorders, and substance use disorders.

• Modular Molecular Architecture:

  • Venus Flytrap (VFT) Domain: Situated at the distal extracellular region; organized into an upper lobe and a lower lobe forming an orthosteric binding cleft reminiscent of a Venus flytrap leaf.

  • Cysteine-Rich Domain (CRD): A rigid linker domain that covalently and mechanically bridges the lower lobe of the VFT directly to the extracellular loops of the transmembrane bundle.

  • Transmembrane Domain ($7\text{TM}$): The embedded membrane domain responsible for recruiting and activating intracellular effectors.

• Downstream Effector Coupling and $G_q$ Signaling Cascade:

  • $mGlu_5$ preferentially couples to the heterotrimeric $G_q$ protein complex consisting of $\alpha_q$, $\beta$, and $\gamma$ subunits.

  • Inactive State: The heterotrimer binds guanosine diphosphate ($\text{GDP}$) within the catalytic pocket of $G\alpha_q$.

  • Activation Event: Interaction with the active $7\text{TM}$ bundle stimulates guanine nucleotide exchange factor (GEF) activity, inducing the release of $\text{GDP}$ and binding of guanosine triphosphate ($\text{GTP}$).

  • Subunit Dissociation: $G\alpha_q-\text{GTP}$ dissociates from the $G\beta\gamma$ heterodimer.

  • Enzymatic Cascade: Active $G\alpha_q$ stimulates phospholipase C (PLC), which hydrolyzes phosphatidylinositol 4,5-bisphosphate ($\text{PIP}_2$) into diacylglycerol (DAG) and inositol 1,4,5-trisphosphate ($\text{IP}_3$).

  • Second Messenger Mobilization: $\text{IP}_3$ mobilizes intracellular calcium ($\text{Ca}^{2+}$) release from the endoplasmic reticulum, quantifiable in vitro by monitoring $\text{IP}_1$ accumulation (a downstream metabolite of $\text{IP}_3$) or direct cytosolic $\text{Ca}^{2+}$ fluorimetry.

• Absolute Lipid Bilayer Requirement for Receptor Function:

  • Detergent-solubilized, purified $mGlu_5$ fails to activate G proteins upon addition of the glutamate analogue quisqualate in GTP-turnover nucleotide exchange assays.

  • Reconstitution of $mGlu_5$ into synthetic lipid nanodiscs (composed of 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine [POPC] and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol [POPG]) fully restores ligand-induced G protein activation.

  • The annular lipid bilayer is strictly required to provide the mechanical environment and lateral membrane pressure necessary to support TM domain reorientation.

• Conformational Transitions During Activation:

  • Apo / Inactive Conformation:

    • VFT upper and lower lobes remain in an open, unliganded conformation.

    • The inter-protomer helices residing at the dimer interface maintain an obtuse angle relative to one another.

    • The CRDs of adjacent protomers are widely separated.

    • The $7\text{TM}$ domains are distant from each other, interacting weakly through a symmetric $\text{TM}5/\text{TM}5$ interface.

    • Distance between lower lobes is approximately $35\,\text{\AA}$.

  • Quisqualate-Bound Active Conformation:

    • Binding of quisqualate inside the cleft induces rapid closure of the upper and lower lobes of the VFT.

    • Inter-protomer helices pivot into an acute angle, pulling the protomers closer together.

    • The structural rearrangement propagates through the CRDs, driving them into close proximity.

    • The $7\text{TM}$ domains undergo a massive inward translation and tilt, breaking the $\text{TM}5/\text{TM}5$ contact and forming a new, active-state $\text{TM}6/\text{TM}6$ interface.

    • Distance between the lower lobes contracts to approximately $10\,\text{\AA}$.

• Identification of an Intermediate State:

  • Single-molecule Fluorescence Resonance Energy Transfer (smFRET) between donor- and acceptor-fluorophores installed on the CRD domains demonstrates:

    • A predominant low-FRET population in the apo state (separated CRDs).

    • A predominant high-FRET population upon quisqualate addition (condensed CRDs).

    • An intermediate, mid-FRET population in agonist-bound conditions.

  • Cryo-EM structural sorting reveals a discrete intermediate structural state from the quisqualate-bound dataset:

    • Quisqualate is fully occupied in the orthosteric binding pocket.

    • VFT upper lobes are closed over the ligand.

    • VFT lower lobes have not yet rotated or fully condensed; CRDs and $7\text{TM}$ domains remain widely separated in an inactive-like disposition.

    • The mid-FRET signal reflects both dynamic conformational exchange and occupancy of this structurally distinct, partially activated intermediate.

Allosteric Modulation by Positive Allosteric Modulators (PAMs)

• Pharmacological Profile of Family C Allosteric Sites:

  • In Family A and B GPCRs, the $7\text{TM}$ bundle forms the orthosteric pocket, while allosteric pockets are typically found elsewhere.

  • In Family C GPCRs, the inverted paradigm applies: the orthosteric site is located in the extracellular VFT, whereas the $7\text{TM}$ bundle functions as an allosteric binding pocket.

  • Positive Allosteric Modulators (PAMs) bind within the $7\text{TM}$ bundle to enhance the affinity, potency, or efficacy of orthosteric agonists (or act as ago-PAMs possessing intrinsic efficacy).

• Structural Impact of PAM Binding:

  • Addition of a PAM to quisqualate-bound $mGlu_5$ eliminates structural conformational heterogeneity.

  • Cryo-EM reconstructions in the presence of quisqualate plus a PAM collapse the multi-state landscape (inactive, intermediate, active) into a single, fully locked active-state ensemble.

  • The inter-protomer VFT helices display complete compaction and elongation, tightly stabilizing the acute inter-helical angle.

• Asymmetric Binding Stoichiometry and Symmetry Breaking:

  • Despite $mGlu_5$ being a homodimer possessing two identical $7\text{TM}$ bundles, only a single PAM molecule binds per dimer.

  • The PAM binding pocket is located directly at the active $\text{TM}6$ dimer interface.

  • Accommodating the PAM requires a conserved tryptophan residue within Protomer 1 to swing outward; mutation of this tryptophan completely ablates PAM binding.

  • Outward displacement of this tryptophan is accompanied by outward motion of $\text{TM}6$ in Protomer 1, orienting an adjacent tyrosine side chain toward $\text{TM}6$.

  • This structural shift forces the $\text{TM}6$ helix of Protomer 2 to pivot inward, which sterically occludes the corresponding allosteric pocket in Protomer 2.

  • Consequently, positive cooperativity is asymmetric: binding of one PAM molecule at one protomer breaks structural symmetry and prevents binding of a second PAM at the opposing protomer.

• Effector Coupling Stoichiometry:

  • Only a single heterotrimeric G protein can engage the $mGlu_5$ homodimer at any given time due to physical steric clashes preventing dual occupancy.

  • PAM binding asymmetrically stabilizes intracellular loop 2 (ICL2) of the occupied protomer, creating an optimal intracellular docking platform that guides G protein engagement specifically to the PAM-bound protomer.

Extracellular Domain Modulation via Conformationally Sensitive Nanobodies

• Generation and Selection of Camelid Nanobodies:

  • Heavy-chain-only antibody variable domains ($\text{V}_{\text{H}}\text{H}$ nanobodies; molecular weight $\sim 15 - 16\,\text{kDa}$) were developed by immunizing llamas (Lama glama) with purified, functional $mGlu_5$.

  • Isolated peripheral lymphocytes were converted into a phage display cDNA library, followed by panning against receptor conformers to enrich for conformationally sensitive binders targeting the extracellular domain.

  • Three distinct clones displaying diverse functional pharmacology were selected for characterization: Nanobody 43 (Nb43), Nanobody 36 (Nb36), and Nanobody 40 (Nb40).

• Pharmacological Characterization of Nanobodies:

  • Nanobody 43 (Nb43) — Full Ago-PAM:

    • Elicits substantial intracellular $\text{Ca}^{2+}$ release on its own in the absence of orthosteric agonist.

    • Produces a concentration-dependent increase in $\text{IP}_1$ accumulation with high potency.

    • Functions as an ago-PAM in bioluminescence resonance energy transfer (BRET) assays monitoring $G\beta\gamma$ release (using an $m\text{Venus}-G\beta\gamma$ donor and GRK3-NanoLuc acceptor sensor), elevating both the potency ($\text{EC}_{50}$) and maximal efficacy ($E_{\max}$) of quisqualate.

    • Directly stimulates GDP-GTP exchange turnover in purified receptor-nanodisc biochemical assays.

  • Nanobody 36 (Nb36) — Partial Ago-PAM:

    • Induces moderate, submaximal elevations in $\text{Ca}^{2+}$ mobilization and $\text{IP}_1$ production.

    • Displays partial ago-PAM activity in BRET-based G protein activation assays, showing intermediate stimulation at baseline and enhancing quisqualate responses suboptimally.

    • Promotes moderate G protein turnover in reconstituted biochemical assays.

  • Nanobody 40 (Nb40) — Allosteric Antagonist / Inverse Agonist:

    • Suppresses baseline signaling and fails to stimulate $\text{Ca}^{2+}$ or $\text{IP}_1$ production.

    • Decreases BRET signals in a concentration-dependent manner, functionally antagonizing quisqualate-mediated activation.

    • Exerts no stimulatory activity in reconstituted G protein turnover assays, maintaining the receptor in a quiescent state.

• Structural Basis of Nanobody Action by Cryo-EM and smFRET:

  • Reconstructions were performed using a Glacios cryo-transmission electron microscope, utilizing local refinement of the extracellular domains to attain resolutions between $3.0\,\text{\AA}$ and $3.5\,\text{\AA}$.

  • Mechanism of Nb43 (Upper Lobe Engagement):

    • Epitope: Binds selectively to the upper surface of the VFT upper lobe.

    • Apo-State Structures: Cryo-EM of apo-$mGlu_5$ in the presence of Nb43 reveals two distinct structural states: an Nb43-bound inactive state and an Nb43-bound partially active state.

    • Structural Metrics: The lower lobe inter-protomer distance measures intermediate between the inactive ($35\,\text{\AA}$) and fully active ($10\,\text{\AA}$) conformations.

    • Dynamics (smFRET): Addition of Nb43 to unliganded receptor splits the population between low-FRET (inactive) and high-FRET (active) conformers; subsequent quisqualate addition shifts the distribution predominantly to the high-FRET state.

    • Biophysical Mechanism: Nb43 acts via conformational selection, capturing and stabilizing the downward-flexed conformation of the upper lobe as the receptor breathes, thereby lowering the free-energy barrier required to achieve full activation.

  • Mechanism of Nb36 (Inter-Lobe Bridging):

    • Epitope: Binds at the lateral surface of the VFT lower lobe.

    • Structural Details: The complementarity-determining regions (CDRs) of Nb36 project across the inter-lobe cleft, making simultaneous physical contacts with both the upper and lower lobes of the VFT.

    • Biophysical Mechanism: By bridging across the clamshell cleft, Nb36 directly staples the upper and lower lobes together, driving clamshell closure even in the absence of quisqualate and enhancing orthosteric agonist potency.

    • Dynamics (smFRET): Produces a modest reduction in the low-FRET state accompanied by an increase in the mid-FRET and high-FRET populations, reflecting enhanced structural fluctuations across the activation pathway.

  • Mechanism of Nb40 (CRD Wedge Antagonism):

    • Epitope: Binds simultaneously to the lower lobe of the VFT and the adjacent Cysteine-Rich Domain (CRD).

    • Structural Metrics: Structurally overlays with small-molecule antagonist-bound $mGlu_5$ conformations.

    • Biophysical Mechanism: Nb40 acts as a physical molecular wedge inserted between the lower lobe and the CRD. This steric block prevents the CRD from rotating and translating toward the central dimer axis, arresting the receptor in an open, inactive architecture.

    • Dynamics (smFRET): Stabilizes the low-FRET population while eliminating the high-FRET active peak, both in the apo state and in the presence of quisqualate.

• Emerging Methodological Directions:

  • Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS) is deployed to track dynamic changes in peptide-level solvent accessibility and map the continuous pathway of allosteric information transfer flowing from the VFT through the CRD down to the $7\text{TM}$ core upon nanobody and modulator binding.

Questions & Discussion

• Lipid Bilayer Reconstitution and Endogenous Lipid Selectivity:

  • Question: Was it possible to resolve ordered, structural lipid molecules in the cryo-EM density maps of the nanodisc-embedded receptor, and is there a functional preference for specific lipids such as cholesterol?

  • Response: The initial cryo-EM density maps did not show resolved boundary or structural lipids directly coordinated to the protein, despite the functional requirement for a lipid environment (since detergent-solubilized receptor is completely inactive). The initial reconstructions utilized synthetic phosphatidylcholine and phosphatidylglycerol (POPC/POPG) mixtures. Ongoing efforts involve reconstituting $mGlu_5$ into native brain lipid extracts to determine whether native physiological lipids modulate baseline activity or structural stabilization; however, batch-to-batch variation inherent in brain-derived lipid preparations represents a significant technical hurdle.

• Symmetry Breaking, G Protein Coupling, and PAM Stoichiometry:

  • Question: Given that orthosteric agonist binds to both VFT lobes across the homodimer, does G protein coupling also break symmetry such that only one G protein engages, and does it bind to the same protomer that coordinates the PAM?

  • Response: Only a single heterotrimeric G protein binds per $mGlu_5$ dimer. Physical steric hindrance prevents two large G protein complexes from docking simultaneously at the two $7\text{TM}$ bundles. While published structures place the PAM on the exact protomer that engages the G protein, PAM binding directly rigidifies and reorganizes intracellular loop 2 (ICL2) on that specific protomer, creating a favorable structural interface that preferentially directs G protein docking to the PAM-bound protomer. Even in the absence of a PAM, G protein binding inherently breaks the dimer symmetry on its own.

• Hemi-Liganded States and Asymmetric VFT Closure:

  • Question: Because experiments rely on super-stoichiometric concentrations of agonist and nanobodies, what would occur if the receptor were forced into a hemi-liganded state (for instance, via a heterodimer with one mutant protomer incapable of binding ligand)? Would one VFT close while the other remains open, and could this explain the smFRET intermediate state?

  • Response: While no structural state of $mGlu_5$ has been solved with one VFT lobe closed and the partner lobe open, this asymmetric conformation has been structurally captured in metabotropic glutamate receptor 1 ($mGlu_1$). There is no fundamental biophysical barrier preventing $mGlu_5$ from adopting a similar asymmetric state. The intermediate mid-FRET population observed in smFRET experiments may correspond to an asymmetric intermediate where one protomer has closed while the second remains open or uncoupled.

• Structural Comparison Between Nb40 and Small-Molecule Antagonists:

  • Question: How does the extracellular architecture of the Nb40-bound complex compare to receptor structures bound to classical inverse agonists or competitive antagonists?

  • Response: The extracellular VFT and CRD architecture of the Nb40-bound receptor aligns with high structural fidelity to antagonist-bound $mGlu_5$ structures. In cryo-EM datasets containing both Nb40 and high concentrations of quisqualate, particle subsets can be resolved where quisqualate overcomes the inhibition to close the VFT; however, smFRET demonstrates that in solution, Nb40 strongly favors and stabilizes the inactive, low-FRET state.

• Physical Mechanism of Nanobody 43 Binding to the Upper Lobe:

  • Question: How can an antibody binding exclusively to the top of the upper lobe drive the closure of the VFT without having an opposing anchor or structural surface to push against?

  • Response: Nanobody 43 does not exert a mechanical directed force or push against an external structural fulcrum. GPCRs are dynamic ensembles that continuously undergo spontaneous conformational fluctuations between open and closed states. Nb43 operates via conformational selection: when the upper lobe transiently flexes downward during thermal breathing, Nb43 binds and selectively traps that closed conformation, shifting the thermodynamic equilibrium. This mechanism mirrors the action of ELFN proteins on $mGlu_7$, which bind to a similar region of the upper lobe but instead trap the domain in an open, inactive conformation to mediate allosteric antagonism.

• Cryo-EM Particle Processing and Sorting of Intermediate States:

  • Question: What proportion of cryo-EM particles occupied the intermediate state, and what computational strategies were used to isolate them during data processing?

  • Response: Determining exact physiological percentages is difficult because many damaged or non-aligning particles are discarded during 2D and 3D classification. However, because side-view projections of Class C GPCRs clearly differentiate whether the CRD linkers are widely separated (inactive/intermediate) or brought together (active), extensive rounds of targeted 2D classification and supervised 3D classification were performed to sort particles displaying separated versus condensed CRDs, ultimately yielding approximately equal numbers of refined particles for the final active and intermediate 3D density maps.